0HF9 Stock Overview A biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. More details
Rewards Risk Analysis No risks detected for 0HF9 from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Amicus Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Amicus Therapeutics Historical stock prices Current Share Price US$9.25 52 Week High US$14.01 52 Week Low US$9.04 Beta 0.61 1 Month Change -7.16% 3 Month Change -9.34% 1 Year Change -31.87% 3 Year Change -10.70% 5 Year Change n/a Change since IPO -42.89%
Recent News & Updates
Third quarter 2024 earnings released: US$0.022 loss per share (vs US$0.073 loss in 3Q 2023) Nov 07
Amicus Therapeutics, Inc. Raises Earnings Guidance for the Year 2024 Nov 06
Amicus Therapeutics, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 28
Second quarter 2024 earnings released: US$0.052 loss per share (vs US$0.15 loss in 2Q 2023) Aug 09 Aug 09
Amicus Therapeutics, Inc. Raises Earnings Guidance for the Year 2024 Aug 08
See more updates
Third quarter 2024 earnings released: US$0.022 loss per share (vs US$0.073 loss in 3Q 2023) Nov 07
Amicus Therapeutics, Inc. Raises Earnings Guidance for the Year 2024 Nov 06
Amicus Therapeutics, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 28
Second quarter 2024 earnings released: US$0.052 loss per share (vs US$0.15 loss in 2Q 2023) Aug 09 Aug 09
Amicus Therapeutics, Inc. Raises Earnings Guidance for the Year 2024 Aug 08
Amicus Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 30
Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024 May 10
First quarter 2024 earnings released: US$0.16 loss per share (vs US$0.18 loss in 1Q 2023) May 09
Amicus Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024 May 03
Amicus Therapeutics, Inc., Annual General Meeting, Jun 06, 2024 Apr 26
Forecast breakeven date pushed back to 2025 Apr 12
Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024 Feb 29
Full year 2023 earnings released: US$0.51 loss per share (vs US$0.82 loss in FY 2022) Feb 29
Amicus Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 28, 2024 Feb 16
Forecast to breakeven in 2024 Jan 09
Amicus Therapeutics, Inc. Provides Revenue Guidance for the Year 2024 Jan 08
Insufficient new directors Jan 01
Amicus Therapeutics Announces Executive Changes Dec 05
Forecast to breakeven in 2024 Nov 29
Third quarter 2023 earnings released: US$0.073 loss per share (vs US$0.12 loss in 3Q 2022) Nov 09
Amicus Therapeutics, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Oct 28 Amicus Therapeutics, Inc. announced that it has received $29.999985 million in funding Oct 17
New minor risk - Share price stability Oct 05
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease Sep 29
New Paradigm Therapeutics, Inc. acquired worldwide rights of SD-101 from Amicus Therapeutics, Inc. (NasdaqGM:FOLD). Aug 24
Amicus Therapeutics, Inc. Announces Chief Financial Officer Changes Aug 22
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom Aug 17
Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.21 loss in 2Q 2022) Aug 09 Amicus Therapeutics, Inc. Announces Retirement of Daphne Quimi as Chief Financial Officer
New minor risk - Share price stability Aug 09
Amicus Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Aug 01
Amicus Therapeutics, Inc. Appoints Samantha Prout as Chief Accounting Officer and Controller Jul 14
Amicus Therapeutics Inc. Announces Approval and Launch of New Pompe Disease Therapy in the European Union Jun 28
Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2023 May 11
First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.30 loss in 1Q 2022) May 10
Full year 2022 earnings released: US$0.82 loss per share (vs US$0.92 loss in FY 2021) Mar 02
Amicus Therapeutics, Inc. to Report Q4, 2022 Results on Mar 01, 2023 Feb 15
Amicus Therapeutics, Inc. Provides Revenue Guidance for the Year 2023 Jan 10
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease Dec 17
Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.19 loss in 3Q 2021) Nov 08
Amicus Therapeutics, Inc. Provides Revenue Guidance for the Full-Year of 2022 Nov 08
Amicus Therapeutics, Inc. Announces U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease Oct 29
Amicus Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022 Oct 28
Executive Chairman recently sold US$112k worth of stock Sep 20
Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.19 loss in 2Q 2021) Aug 05
Amicus Therapeutics, Inc. Provides Guidance for 2022 Aug 05
Amicus Therapeutics, Inc. Appoints Bradley L. Campbell as Chief Executive Officer Aug 02
Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA May 12
First quarter 2022 earnings released: US$0.30 loss per share (vs US$0.25 loss in 1Q 2021) May 10 Amicus Therapeutics, Inc. Provides Revenue Guidance for the Full Year of 2022 May 10
Forecast breakeven date pushed back to 2024 Feb 26
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 25
Amicus Therapeutics, Inc. to Report Fiscal Year 2021 Results on Feb 24, 2022 Feb 11
Amicus Therapeutics, Inc. Provides Unaudited Revenue Guidance for the Year 2021 and 2022 Jan 12
European Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applications for AT-GAA for the Treatment of Pompe Disease Dec 05
Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.25 loss in 3Q 2020) Nov 10
High number of new directors Oct 31
Forecast to breakeven in 2023 Oct 01
Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.20 loss in 2Q 2020) Aug 06
Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease Aug 04
Amicus Therapeutics Announces United Kingdom’s MHRA Grants Early Access to AT-GAA Jun 09
Independent Director recently bought US$250k worth of stock May 30
First quarter 2021 earnings released: US$0.25 loss per share (vs US$0.35 loss in 1Q 2020) May 11
Amicus Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2021 May 11
Amicus Therapeutics, Inc. Announces Successful Pre-BLA Meeting with U.S. FDA for AT-GAA for the Treatment of Pompe Disease May 05
Full year 2020 earnings released: US$1.07 loss per share (vs US$1.48 loss in FY 2019) Mar 05
Revenue beats expectations Mar 05
Amicus Therapeutics, Inc. to Report Fiscal Year 2020 Results on Mar 01, 2021 Feb 18
Amicus Therapeutics, Inc. Announces Topline Results of its Phase 3 PROPEL Pivotal Trial for AT-GAA Feb 12
Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy At the 17Th Annual WorldSymposium™ 2021 Feb 09
Amicus Therapeutics Announces Presentations and Posters Jan 23 Shareholder Returns 0HF9 GB Biotechs GB Market 7D -1.8% -0.3% 0.6% 1Y -31.9% -24.5% 4.6%
See full shareholder returns
Return vs Industry: 0HF9 underperformed the UK Biotechs industry which returned -24.5% over the past year.
Return vs Market: 0HF9 underperformed the UK Market which returned 4.6% over the past year.
Price Volatility Is 0HF9's price volatile compared to industry and market? 0HF9 volatility 0HF9 Average Weekly Movement 6.3% Biotechs Industry Average Movement 9.5% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.6% 10% least volatile stocks in GB Market 2.5%
Stable Share Price: 0HF9 has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0HF9's weekly volatility (6%) has been stable over the past year.
About the Company Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline.
Show more Amicus Therapeutics, Inc. Fundamentals Summary How do Amicus Therapeutics's earnings and revenue compare to its market cap? 0HF9 fundamental statistics Market cap US$2.80b Earnings (TTM ) -US$104.69m Revenue (TTM ) US$493.67m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0HF9 income statement (TTM ) Revenue US$493.67m Cost of Revenue US$49.43m Gross Profit US$444.24m Other Expenses US$548.93m Earnings -US$104.69m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.35 Gross Margin 89.99% Net Profit Margin -21.21% Debt/Equity Ratio 217.8%
How did 0HF9 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/08 23:44 End of Day Share Price 2025/01/08 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Amicus Therapeutics, Inc. is covered by 28 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution John Eade Argus Research Company Michael Ulz Baird Yun Zhong Berenberg
Show 25 more analysts 
